Oruka Therapeutics general counsel sells $706k in shares

Paul T. Quinlan, General Counsel at Oruka Therapeutics, Inc. (NASDAQ:ORKA), executed a series of transactions involving the company’s common stock on October 20, 2026. Quinlan sold a total of 9,000 shares for an aggregate value of $706,734, with prices ranging from $74.47 to $79.72 per share. These sales were made pursuant to a Rule 10b5-1 trading plan established on May 15, 2026. The timing coincides with remarkable stock performance, as shares have delivered a 189% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, placing it among companies on the most overvalued list.

Prior to the sales, Mr. Quinlan acquired 9,000 shares of Oruka Therapeutics common stock by exercising employee warrants. These shares were acquired at an exercise price of $7.80 per share, totaling $70,200. The warrants vest as to 1/4 of the underlying shares on April 30, 2025, and as to 1/48 of the underlying shares monthly from April 30, 2025.

Following these transactions, Paul T. Quinlan beneficially owns 29,995 shares of Oruka Therapeutics common stock.

In other recent news, Oruka Therapeutics has garnered attention with its latest developments. The company reported positive results from its EVERLAST-A Phase 2a trial for the psoriasis treatment ORKA-001, showing increased efficacy. Specifically, PASI 100 response rates improved to 71.4% at Week 28 from 63.5% at Week 16, while PASI 90 rates rose to 87.3%. Piper Sandler has reiterated an Overweight rating on Oruka Therapeutics, maintaining a price target of $180, citing the strength of the company’s drug pipeline. Similarly, H.C. Wainwright reiterated a Buy rating with a $120 price target, acknowledging the promising trial outcomes. In addition, Oruka Therapeutics recently appointed Todd Edwards as Chief Commercial Officer, bringing over 25 years of experience in commercial leadership. These updates reflect the company’s strategic moves and ongoing efforts in advancing its treatment offerings.